December 17, 2013 4:19 PM | 1 min read
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Transcept Pharmaceuticals (Nasdaq: TSPT) today commented on the recent announcements from Retrophin (OTC: RTRX) that it has withdrawn its unsolicited overture to purchase all of the shares of Transcept, and that Retrophin is no longer a Transcept stockholder, indicating that such overture from Retrophin was not a bonafide offer."The Board of Directors of Transcept did not consider the unsolicited indication of interest from Retrophin, Inc. of $4.00 per share to be a bonafide offer, as Retrophin never presented any credible evidence of their ability to finance the purchase of our stock. With the newly announced support of our largest stockholder, Roumell Asset Management, Transcept intends to continue to move forward to execute strategies to enhance stockholder value," stated Glenn A. Oclassen, President and Chief Executive Officer.
See full press release
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.